Librela (bedinvetmab) is a monoclonal antibody therapy that targets nerve growth factor (NGF), a key driver of osteoarthritis pain in dogs. By neutralizing NGF, Librela disrupts the pain signals caused by inflammation and joint degeneration, providing long-term relief. Librela works differently from traditional pain medications, offering a targeted and innovative approach to pain management with fewer side effects.